122 results about "Egg phospholipids" patented technology

The invention provides an AS01 derivative adjuvant, a preparation method thereof and application of the AS01 derivative adjuvant in preparation of vaccines or anti-tumor drugs, and belongs to the technical field of biological drugs or products. The AS01 derivative adjuvant is prepared from the following components in parts by mass: 0.5 to 1.0 part of cholesterol, 2.0 to 4.0 parts of dioleoyl lecithin and at least one of the following components in parts by mass: 0.1 to 0.2 part of monophosphoryl lipid A, 0.1 to 0.2 part of QS-21, 0.36 to 0.72 part of 3M-052, 0.4 to 0.8 part of muramyl dipeptide and 0.2 to 0.4 part of oligodeoxynucleotide. According to the AS01 derived adjuvant, a novel synergistic adjuvant system is developed by integrating various immunomodulators, so that the immunogenicity of a vaccine is enhanced. The HPV vaccine is prepared on the basis of the AS01 derived adjuvant, so that the immunogenicity can be enhanced, and good anti-tumor activity can be achieved. Therefore, the invention provides a new strategy for immunotherapy of HPV-related tumors.

The invention discloses a hair follicle targeting nano-liposome anti-hair loss and hair growth compound preparation. The compound preparation is prepared from the following raw materials in parts by mass: 70 to 85 parts of bionic liposome carrier and 15 to 30 parts of active ingredients, the bionic liposome carrier is prepared from 50 to 60 parts of egg yolk lecithin, 15 to 20 parts of pH sensitive phospholipid DOPE, 10 to 15 parts of cholesterol and 5 to 10 parts of mesenchymal stem cell exosome membrane protein; the active ingredients comprise 5 to 10 parts of minoxidil, 3 to 5 parts of caffeine, 0.5 to 1 part of miR-218-5p, 1 to 2 parts of biotin and 2 to 3 parts of quercetin; the average particle size of the nano-liposome formed by the bionic liposome carrier is 120-180nm, and the polydispersity index (PDI) is less than or equal to 0.15. The invention relates to the technical field of biological medicines, in particular to a hair follicle-targeted nano-liposome anti-hair loss and hair growth compound preparation, which has the following advantages due to the adoption of the technical scheme: accurate targeted delivery is realized, and the treatment safety and accuracy are improved; intelligent response release is achieved, and the local microenvironment of hair follicles is optimized; the multi-target synergistic effect breaks through the limitation of single treatment.

The invention discloses a lipophilic liposome containing polydeoxyribonucleotide as well as a preparation method and application of the lipophilic liposome. The lipophilic liposome comprises the following components in parts by weight: 0.001-3 parts of polydeoxyribonucleotide; 0.5 to 3 parts of phospholipid; 0.1-2 parts of a cationic emulsifier; 0.1-3 parts of an anionic emulsifier; 40 to 70 parts of polyol; the total amount is 100 parts. According to the invention, an emulsifier system formed by combining lecithin with anionic and cationic compound surfactants is adopted, so that the transdermal absorption of PDRN is facilitated. The lipophilic liposome containing polydeoxyribonucleotide prepared by the invention can effectively resist nuclease degradation, prolong the acting time of PDRN in skin, and improve the skin anti-aging and repairing effects of the liposome. The anti-aging effect of the active ingredients is improved, and the bioavailability of the active ingredients is improved. The cosmetic composition can be widely applied to cosmetic formulas of various dosage forms.

The invention relates to the technical field of nano drug loading, in particular to chlorin e6 composite liposome as well as a preparation method and application thereof. The preparation method comprises the following steps: dissolving egg yolk lecithin, cholesterol and chlorin e6 in an organic solvent, carrying out rotary evaporation in a constant-temperature water bath kettle to evaporate the solvent to dryness to form a lipoid film, adding a crocin aqueous solution, carrying out high-shear dispersion on the film, carrying out ultrasonication, and filtering with a 0.22 [mu] m filter membrane to obtain the chlorin e6 composite liposome. The chlorin e6 composite liposome prepared by the invention is high in encapsulation efficiency and good in stability, and has the effects of enhancing tumor cell uptake and killing tumor cells through photodynamic.

The invention relates to a novel camellia saponin derivative feed additive and a preparation method thereof, and belongs to the technical field of feed additives. The modified chitosan is used in the flocculation and impurity removal process for preparing the camellia oleifera saponin derivative, and the modified chitosan reduces the loss of effective components caused by flocculation and impurity removal while ensuring the purity of the camellia oleifera saponin derivative; soybean lecithin and gelatin are used as capsule walls, the camellia saponin derivative and pyropheophorbide-a are wrapped, pyropheophorbide-a can generate singlet oxygen under excitation of visible light, phospholipid bonds are damaged, the camellia saponin derivative is released, and therefore the slow release effect is achieved; the novel camellia saponin derivative feed additive prepared by the invention has good antibacterial property and timeliness.

The invention relates to the technical field of nano-material drug delivery, in particular to a loaded peptide and doxorubicin hydrochloride liposome as well as a preparation method and application thereof. Comprising the following steps: (1) dissolving hydrogenated soybean lecithin and cholesterol in ethanol, and filtering with a filter membrane for later use; (2) dissolving peptide CH3 (CH2) 6CO-GIIKKIIKKI-NH2 and doxorubicin hydrochloride into pure water, and filtering with a filter membrane for later use; and (3) taking the phospholipid-cholesterol ethanol solution and the peptide-doxorubicin hydrochloride aqueous solution prepared in the step (2) as organic phases, and preparing the liposome loaded with peptide and doxorubicin hydrochloride by adopting a microfluidic method and controlling the total flow velocity and the flow velocity ratio of the aqueous phase to the organic phase. The prepared liposome is spherical, uniform in particle size, and good in biocompatibility and biodegradability. And no surfactant or dispersant is added in the preparation process, so that the toxicity to the body is further reduced.

The invention provides a silibinin mixed micelle injection as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The cholate / lecithin mixed micelle system constructed by adopting specific cholic acid and phospholipid has good stability, can be well compatible with the silibinin so as to well encapsulate the silibinin, can obviously improve the solubility of the silibinin, has higher safety under the condition of ensuring the stability of the silibinin, and can be used for preparing a medicine for treating the silibinin. Therefore, the bioavailability of the silibinin is greatly improved. According to the invention, a shearing dispersion method is adopted to prepare the mixed micelles, and the mixed micelles with high drug loading capacity, clarification and good stability for silibinin are formed by destroying and shearing the raw and auxiliary materials in a molecular level, so that the mixed micelles have better physical and chemical stability, the drug quality is easier to control, the process is more simplified, the clinical medication is safer and the cost is lower; and the accessibility of the medicine is improved.

The invention discloses a drug-loaded protein-phospholipid composite nanoparticle as well as a preparation method and application thereof. The drug-loaded protein-phospholipid composite nanoparticle has a core-shell structure, an inner core comprises silk fibroin and a hydrophilic drug, a shell layer comprises a plurality of phospholipid bimolecular layers which are stacked layer by layer, each phospholipid bimolecular layer comprises soya bean lecithin, a hydrophobic drug is embedded in a hydrophobic region in each phospholipid bimolecular layer, and the hydrophobic drug is embedded in a hydrophobic region in each phospholipid bimolecular layer. Silk fibroin and a hydrophilic drug are embedded in the hydrophilic area, and zein and cholesterol are embedded in the phospholipid bilayer. The drug-loaded protein-phospholipid composite nanoparticle can simultaneously embed a hydrophobic drug and a hydrophilic drug, has the advantages of large drug loading capacity, high bioavailability, good stability, good transdermal permeation effect and the like, has wide application prospects in the fields of transdermal drug delivery preparations and skin care products, and is simple in preparation method, mild in reaction condition and suitable for industrial production. The method is suitable for large-scale industrial production and application.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a cell membrane protein fusion lipidosome and a preparation method and application thereof.The cell membrane protein fusion lipidosome is prepared from dioleoyl lecithin, 1, 2-propylene glycol and 1, 3-propylene glycol according to the mass ratio of (3.17-7.17): (0.96-2.87): (0.86-2.57): (0.5-2.5): (0.5-2.5). The preparation method comprises the following steps of: adding 1, 2-distearoyl-sn-glycerol-3-phosphoethanolamine-N-[carboxyl (polyethylene glycol)-2000], cholesterol, triton X-100 and cell membrane protein; according to the cell membrane protein fusion liposome provided by the invention, the membrane protein loading rate is remarkably improved, and a technical support is provided for clinical application of a cell membrane material.

The invention discloses a calcium liposome for promoting bone health as well as a preparation method and application thereof. The calcium liposome is prepared from the following components in parts by weight: 3 to 7 parts of phospholipid composition, 0.1 to 0.35 part of phytosterol, 1 to 5 parts of insoluble calcium, 1 to 7.5 parts of protein and 0.1 to 1 part of modifier, wherein the phospholipid composition consists of egg yolk lecithin, phosphatidylinositol and distearoyl phosphatidylcholine, and the mass ratio of the egg yolk lecithin to the phosphatidylinositol to the distearoyl phosphatidylcholine is (8-12): (7-11): ( The specific phospholipid composition obtained through screening is combined with phytosterol to serve as a membrane material to wrap a compound of insoluble calcium and protein, so that the dispersity and the stability of the prepared calcium liposome are obviously improved, when the calcium liposome is applied to preparation of calcium soft capsules, the oil leakage phenomenon is obviously reduced, meanwhile, the absorption of an organism to calcium is also enhanced, and the bioavailability of the calcium soft capsules is improved. Particularly, the bone mineral density and the bone calcium content of an organism are obviously increased, healthy development of bones is promoted, and the difficulty and the pain point of insoluble calcium applied to the fields of functional foods, health care products, biological medicines and the like are effectively solved.

The invention discloses bionic lipidosome co-drug-loaded nanoparticles as well as a preparation method and application thereof, and relates to the technical field of new dosage form pharmaceutical preparations. The preparation method comprises the following steps: loading hydroxysafflor yellow A and statins into double layers or a core of a liposome, adding a biomimetic membrane on the outer layer of the liposome and modifying with phosphatidylated hyaluronic acid to obtain the biomimetic liposome co-drug-loaded nano-particles with the particle size of 60-100 nm; wherein the liposome is prepared from lecithin and cholesterol; the biomimetic membrane is prepared from macrophages; the phosphatidylated hyaluronic acid is prepared from 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N-hydroxysuccinimide, hyaluronic acid and phospholipid polyethylene glycol amino groups, and the phosphatidylated hyaluronic acid is prepared from the phosphatidylated hyaluronic acid, the N-hydroxysuccinimide, the hyaluronic acid and the phospholipid polyethylene glycol amino groups. According to the invention, two medicines can be loaded at the same time and can be sent to a lesion area at the same time.

The invention belongs to the technical field of pharmaceutical preparations. The invention discloses a nano preparation for inhibiting tumor metastasis, a preparation method and application. The nano preparation for inhibiting tumor metastasis comprises liposome spheres and nano spheres. The liposome sphere provided by the invention comprises an inner-layer core structure and a shell wrapping the outer layer of the inner-layer core structure, wherein the inner-layer core structure comprises lecithin, dioleoyl phosphatidyl ethanolamine, cholesterol succinic acid monoester, cholesterol, imidazolyl-cholesterol and DSPE-PEG2000-CS; the core structure of the inner layer is loaded with aspirin and DNaseI; the housing includes platelets. The nano preparation for inhibiting tumor metastasis can dissolve NET, inhibit the platelet function and disintegrate tumor cell-platelet-NET aggregate, and the nanosphere for inhibiting the far-end metastasis of tumors can deeply permeate into the tumors to play a role in killing the tumors.

The present application provides the use of drug-loaded lipid nanocarriers in the preparation of drugs for treating drug-resistant lung cancer, wherein the drug-loaded lipid nanocarriers are made of raw materials including lecithin, cholesterol, distearoylphosphatidylethanolamine-polyethylene glycol-amino, osimertinib, and anlotinib hydrochloride, and are modified with EGF. The drug-loaded lipid nanocarriers can be significantly enriched in tumor tissues, effectively inhibit the proliferation of non-small cell lung cancer cells, and effectively reduce the acquired drug resistance of non-small cell lung cancer to EGFR-TKI. In vivo experiments in mice have shown that the nanoliposome drug delivery system has a better tumor inhibition effect than the combination of simple osimertinib and anlotinib.

The invention relates to an asparagine endopeptidase inhibitor neuronal targeting liposome and a preparation method thereof. The liposome comprises the following components: lecithin, cholesterol, phospholipid polyethylene glycol polypeptide, a fluorescent dye and an asparagine endopeptidase inhibitor. The preparation method has relatively good drug loading capacity and entrapment efficiency; after being atomized and dosed through a nose, the nebulizer can smoothly enter the brain of a mouse through a blood brain barrier to be distributed, and has good biocompatibility; according to the invention, DNA damage and ROS reaction of irradiated brain neurons and glial cells can be reduced, and the research and development value and important academic significance of the liposome for assisting in improving radiation brain injury are revealed.

The invention provides a multifunctional cisplatin liposome as well as a preparation method and application thereof. The liposome is prepared from epigallocatechin gallate, cis-platinum, zinc peroxide nanoparticles, a distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 long-acting fragment, a distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-oestrone targeting fragment, lecithin and cholesterol, and the particle size of the liposome is 80 to 130 nm. According to the multifunctional liposome disclosed by the invention, the zinc peroxide nanoparticles are introduced, so that the function of slowly releasing oxygen in a tumor microenvironment can be realized, and oxygen deficit is reversed; through targeting fragment modification, an active targeting effect can be realized by combining with an estrogen receptor highly expressed on the surface of a breast cancer cell; the epigallocatechin gallate and cis-platinum are co-loaded, so that the sensitivity of chemotherapeutic drugs can be improved, the toxic and side effects of the chemotherapeutic drugs are reduced, a good breast cancer resisting effect is achieved, and the tumor volume is remarkably reduced.

The invention provides an LPC liposome preparation for brain-targeted delivery of chemotherapeutic drugs as well as a preparation method and application of the LPC liposome preparation. The LPC liposome preparation comprises L-alpha-lysophosphatidylcholine, egg yolk lecithin and cholesterol, and the mass of the L-alpha-lysophosphatidylcholine is 5%-30% of the total mass of the L-alpha-lysophosphatidylcholine, the egg yolk lecithin and the cholesterol. The constructed LPC lipidosome can accelerate endocytosis of the lipidosome in bECs, and the lipidosome is transferred to an endosome recovery way by up-regulating p62, so that the lipidosome is prevented from entering a lysosome degradation way, and the transendocytosis efficiency is remarkably improved.

The invention provides ROS (reactive oxygen species)-responsive cationic liposome-loaded tryptanthrin as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The ROS response cationic liposome loaded tryptanthrin disclosed by the invention comprises an ROS response cationic liposome and tryptanthrin which is entrapped in the ROS response cationic liposome; the ROS response cationic liposome is prepared from the following raw materials: egg yolk lecithin, cholesterol, DSPE-TK-PEG (distearoyl phosphatidylcholine) and DOTAP (dioctyl phthalate). In view of significant increase of intestinal local active oxygen under the ECLS condition, the ROS-responsive cationic liposome is adopted to wrap tryptanthrin, so that tryptanthrin is selectively released in an intestinal injury area, whole body exposure is reduced, and meanwhile, the protection effect on the intestinal tract is enhanced.

The present invention provides a nutritional composition comprising milk phospholipids and egg phospholipids, particularly suitable as a nutritional composition for infants, also as a nutritional support product for pregnant women and as a nutritional supplement for the elderly, in which phosphatidylcholine and sphingomyelin and hence choline are also highly correlated. The invention provides a nutritional composition containing choline with high bioavailability.

The invention discloses a docetaxel-based liposome drug delivery system as well as a preparation method and application thereof, and belongs to the technical field of anti-tumor nano-drugs. The delivery system is composed of an active pharmaceutical ingredient docetaxel and a specific excipient, and comprises egg yolk lecithin, phosphatidylserine, taraxasterol, protamine oligopeptide, a necessary stabilizer and a necessary pH regulator. Through an optimized preparation process, the nano drug delivery system with good stability is successfully constructed. Experiments show that the liposome is high in encapsulation efficiency and has a good application prospect.

This invention relates to the field of asiaticoside technology, and discloses asiaticoside liposome compositions, preparation methods, and applications. Specifically, based on molecular design principles, monoprotonated tertiary amine permeation enhancers and diprotonated tertiary amine permeation enhancers are synthesized. Using egg yolk lecithin, cholesterol, monoprotonated or diprotonated tertiary amine permeation enhancers, and asiaticoside as raw materials, asiaticoside liposome compositions are prepared by thin-film dispersion. The liposome composition exhibits a transdermal permeability of >90% after 48 hours, demonstrating excellent transdermal performance, and also possesses excellent encapsulation and drug loading properties, making it suitable for preparing gel formulations for treating skin lesions.

The invention relates to irinotecan liposome combined administration for treating colorectal cancer. Specifically, the invention relates to application of irinotecan lipidosome combined with oxaliplatin, 5-fluorouracil, calcium folinate and bevacizumab in preparation of medicines for treating colorectal cancer, and the irinotecan lipidosome contains hydrogenated soybean lecithin, polyethylene glycol 2000-distearoyl phosphatidyl ethanolamine and cholesterol.

A Neorhizobium huautlense strain CNBG-PGPR-21 and uses thereof. The Neorhizobium sp. CNBG-PGPR-21 was deposited in China General Microbiological Culture Collection Center (CGMCC) on August 1st, 2022,

The invention relates to a preparation method of a pulmonary surfactant fusion type nano bionic body, which comprises the following steps: mixing dipalmitoyl phosphatidylcholine, 1-palmitoyl-2-oleoyl-lecithin, cholesterol and dipalmitoyl phosphatidyl glycerol together, adding into chloroform, carrying out vortex oscillation, uniformly mixing to form a lipid solution, adding into an eggplant-shaped bottle filled with chloroform, adding a medicine, uniformly stirring, and carrying out vacuum drying to obtain the pulmonary surfactant fusion type nano bionic body. And after the solvent is completely removed, a layer of uniform white thin film can be obtained on the inner wall of the eggplant-shaped bottle, adding water for dissolving, and carrying out ice-bath ultrasonic detection treatment on the obtained lipid thin film solution by using an ultrasonic cell disruptor, thereby obtaining the product. The method disclosed by the invention is easy to operate, can be used for effectively preparing the lung surfactant fusion type nano biomimetic body, is used for loading a medicine for treating lung diseases to directly reach a lung focus and fully exerting the medicine effect, is good in targeting effect, improves the treatment effect, opens up a new way for treating the lung diseases, and has remarkable economic and social benefits.

The invention discloses a soybean protein-phospholipid biomimetic membrane as well as a preparation method and application thereof. The biomimetic membrane is formed by three raw materials of soybean protein, soybean lecithin and a charged polymer through electrostatic interaction and a physical blending method. The soybean 11s protein solution, the lipidosome dispersion liquid and the charged polymer solution are mixed to obtain the mosaic structure biomimetic membrane which is formed by combining various chemical bond crosslinking and electrostatic interaction, and the process conditions are simple, efficient, convenient and environmentally friendly. The biomimetic membrane provided by the invention has a mosaic structure and the characteristics of the raw materials, so that the biomimetic membrane has high ion passing rate, strong ion selection capability, excellent monovalent cation and divalent cation separation capability and certain biodegradability. When the biomimetic membrane is applied to ion separation, the separation capacity of ions with different valence states can be effectively improved, the separation effect of sodium ions and magnesium ions is optimal, and the separation factor is as high as 21.28 and is 54.6 times that of a biomimetic membrane without charges.

The present invention provides a nutritional composition especially well suited as an infant nutritional composition, but also as a nutritional support product for pregnant women and as senior nutritional supplement, where phosphatidylcholine and sphingomyelin, and thus choline, also are highly relevant. The present invention provides a nutritional composition which contains choline of high bio-availability.

The application relates to the field of biological medicine, and discloses ascorbyl palmitate nanoliposomes capable of inducing tumor cell oncosis, a preparation method and application thereof. The nanoliposomes are constructed by inserting ascorbyl palmitate as a lipid component into a phospholipid bilayer, and are prepared by a film dispersion method from lecithin, cholesterol, pegylated phospholipid and ascorbyl palmitate. The average particle size of the nanoliposomes is 80-150 nm, the encapsulation rate is high, and the stability is good. The nanoliposomes can be administered through a tail vein, utilize the specific hydrolysis of matrix metalloproteinase MMP-2 which is highly expressed by tumor cells to hydrolyze ascorbyl palmitate, release palmitic acid and ascorbic acid, thereby inducing Caspase-independent oncosis of tumor cells, effectively overcoming apoptosis-related drug resistance, and reversing a tumor immunosuppressive microenvironment. The nanoliposomes avoid the cumulative toxicity of metal-type inducers, and provide a new safe and effective option for reversing chemotherapy resistance.

Emulsion formulations and systems for the intravenous or parenteral administration of neurokinin-1 (NK-1) receptor antagonists for treatment of emesis are provided. Methods for preparing the stable NK-1 receptor antagonist emulsions and pharmaceutical formulations are further provided. The emulsion formulations are prepared and characterized as a formulation and process that will allow an NK-1 receptor antagonist compound to be incorporated into an emulsion for intravenous injection and remain stable during the shelf life of the formulation. Specifically, emulsion formulations have an oil phase that includes oil, ethanol, egg lecithin, and the further addition of sodium oleate that is mixed with an aqueous phase and processed to form the emulsion formulation.

The invention discloses a stable vitamin K1 micelle solution and a preparation method thereof, the vitamin K1 micelle solution comprises 0.75%-1.25% of vitamin K1, 5%-6% of egg yolk lecithin or soybean lecithin, 5.5%-6.5% of polyethylene glycol 1000 vitamin E succinate, a pH regulator and water for injection, and the pH value of the micelle solution is 4.5-6.5. According to the invention, phospholipid and polyethylene glycol 1000 vitamin E succinate (TPGS) are selected as emulsifiers, so that the dissolution of vitamin K1 is solved, the degradation of vitamin K1 is avoided, and the stability of the product is improved; according to the invention, the polyethylene glycol 1000 vitamin E succinate (TPGS) is used, the tocopherol structure of the TPGS has a relatively strong antioxidant function, the content of related impurities of the vitamin K1 is remarkably reduced, and the vitamin K1 has better stability; by controlling the particle size of the micelle to be 65-80 nm, the obtained solution is milky white to faint yellow, and the influence of illumination on the stability of the product is avoided.

A process for producing a triglyceride-phospholipid concentrate is provided, the process comprising: providing an egg yolk lecithin solution from the extraction of an egg yolk material with a liquid extractant, mixing the egg yolk lecithin solution with an OPO triglyceride carrier comprising 1,3-dioleoyl-2-palmitoylglycerol and having a ratio of palmitic acid in the 2-position of the triglycerides relative to the total palmitic acid in the triglycerides (SN2-C16:0) of at least 50%, and a C52 triglyceride content of at least 42 wt.%, and separating the liquid extractant from the mixture to produce a triglyceride- phospholipid concentrate comprising the OPO triglyceride carrier and egg lecithin.

The invention provides a transdermal glabridin nano composition as well as a preparation method and application thereof. The transdermal glabridin nano composition is prepared from oil-phase raw materials: glabridin, soya bean lecithin, an emulsifier and butanediol; the water-phase raw materials comprise p-hydroxyacetophenone, an emulsifier, butanediol, bis (lauramide glutamine) sodium lysine and water. According to the glabridin liposome and the preparation method thereof, the stability of the glabridin liposome, especially the stability at a relatively high temperature, is effectively improved by selecting the proper emulsifier, the storage difficulty of related cosmetics and medical products is reduced, and a good foundation is provided for wider application of the related cosmetics and medical products.